Myriad Genetics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 31.2 million compared to USD 42.3 million a year ago. Basic loss per share from continuing operations was USD 0.36 compared to USD 0.52 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.25 USD | +5.43% | +31.37% | +31.92% |
05-08 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
05-08 | Myriad Genetics Shares Rise After Reporting Narrower Q1 Adjusted Loss, Higher Revenue | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.92% | 2.17B | |
-1.34% | 12.58B | |
-1.64% | 8.51B | |
+0.09% | 5.29B | |
+22.42% | 5.16B | |
-0.09% | 4.55B | |
-52.84% | 3.04B | |
+20.02% | 3B | |
-2.45% | 1.92B | |
+6.45% | 1.64B |
- Stock Market
- Equities
- MYGN Stock
- News Myriad Genetics, Inc.
- Myriad Genetics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023